Alana Rachel Wong
Pathogenetic mechanisms in T-ALL
Using our recently developed cord blood transduction approach, we are able to generate synthetic T-ALL by de novo transformation of normal human hematopoietic progenitors with activated NOTCH1 in combination with accessory oncogenes (M. Kusakabe et al, Nature Communications, 2019). This model generates polyclonal expansions of pre-leukemia cells in vitro within 3-4 weeks, which then produce clonal T-ALL disease within 3 months after injection into immunodeficient mice. Using this model, we are actively exploring the following areas:
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.